NCT00036062

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 600 (planned)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

Detailed description

Acute lung injury often develops as a result of severe infection, sepsis, severe injuries, inhalation of foreign substances into the lungs, or pneumonia. The tissues and blood vessels in the lungs become inflamed, and the body does not receive enough oxygen. Patients with this condition are placed on a ventilator to assist with breathing. Patients entered into this study will be randomly assigned to one of two treatment groups: a sivelestat group or a placebo group. Once entered into the study, patients are monitored for up to 6 months.

Conditions

• Respiratory Distress Syndrome, Adult
• Acute Lung Injury

Interventions

Type	Name	Description
DRUG	Sivelestat

Timeline

• Start date: 2001-08-01
• Completion: 2002-12-01
• First posted: 2002-05-08
• Last updated: 2006-07-19

Locations

110 sites across 6 countries: United States, Australia, Belgium, Canada, New Zealand, Spain